-
Something wrong with this record ?
Alternative methods in vitro for screening of endocrine disruptors
M. Dvořáková, K. Kejlová, H. Bendová, M. Rucki, P. Kohout, A. Vavrouš, D. Jírová,
Language English Country Sweden
Document type Journal Article
PubMed
28263540
Knihovny.cz E-resources
- MeSH
- Estrogen Receptor alpha agonists antagonists & inhibitors metabolism MeSH
- Benzhydryl Compounds metabolism MeSH
- Biological Assay MeSH
- Cell Line MeSH
- Endocrine Disruptors metabolism MeSH
- Phenols metabolism MeSH
- Humans MeSH
- Estrogens, Non-Steroidal metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: The aim of this study was to compare in silico data with results obtained in two alternative in vitro methods; and to investigate the potential endocrine activity of bisphenol A analogues. This article contributes to recent findings and brings up-to-date information on development of EU legislation and in vitro testing methods of endocrine disruption. METHODS: In silico approach based on the OECD QSAR Toolbox was used for prediction of potential ligands of human estrogen receptor α. Estrogen Receptor Transactivation in vitro Assay to Detect Estrogen Receptor Agonists and Antagonists (OECD TG 455/457) using the VM7Luc4E2 (formerly designated BG1Luc4E2) cell line was performed for measurement of transactivation activity of the tested substances. Commercially available yeast-based microplate assay (XenoScreen YES/YAS, Xenometrix, Switzerland) for detection of compounds with estrogenic and androgenic agonistic/antagonistic activity was used as a comparative test to estrogen receptor transactivation assay (OECD TG 455/457) and for screening of the agonistic/antagonistic potential of human estrogen receptor and agonistic/antagonistic activity of tested compounds on human androgen receptor. RESULTS: The study showed good correlation between the two in vitro assays and significant correlation with in silico data. All tested substances were identified as agonists for human estrogen receptor α by methods in silico and in vitro, four substances showed a potentially higher estrogenic activity comparing to bisphenol A, two substances were identified as very weak antagonists of human androgen receptor and one compound showed a potential of agonistic activity to human androgen receptor. CONCLUSIONS: The study contributes to recent findings and brings new in silico and in vitro data of bisphenol A analogues, revealing that these analogous substances should be further tested as they may show similar or higher activity in vivo comparing to bisphenol A, which has been recently legislatively regulated.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023225
- 003
- CZ-PrNML
- 005
- 20240321093813.0
- 007
- ta
- 008
- 170720s2016 sw f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)28263540
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Dvořáková, Markéta, $d 1977 leden 17.- $u Third Faculty of Medicine, Charles University, Prague, Czech Republic. National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic. $7 xx0267267
- 245 10
- $a Alternative methods in vitro for screening of endocrine disruptors / $c M. Dvořáková, K. Kejlová, H. Bendová, M. Rucki, P. Kohout, A. Vavrouš, D. Jírová,
- 520 9_
- $a OBJECTIVES: The aim of this study was to compare in silico data with results obtained in two alternative in vitro methods; and to investigate the potential endocrine activity of bisphenol A analogues. This article contributes to recent findings and brings up-to-date information on development of EU legislation and in vitro testing methods of endocrine disruption. METHODS: In silico approach based on the OECD QSAR Toolbox was used for prediction of potential ligands of human estrogen receptor α. Estrogen Receptor Transactivation in vitro Assay to Detect Estrogen Receptor Agonists and Antagonists (OECD TG 455/457) using the VM7Luc4E2 (formerly designated BG1Luc4E2) cell line was performed for measurement of transactivation activity of the tested substances. Commercially available yeast-based microplate assay (XenoScreen YES/YAS, Xenometrix, Switzerland) for detection of compounds with estrogenic and androgenic agonistic/antagonistic activity was used as a comparative test to estrogen receptor transactivation assay (OECD TG 455/457) and for screening of the agonistic/antagonistic potential of human estrogen receptor and agonistic/antagonistic activity of tested compounds on human androgen receptor. RESULTS: The study showed good correlation between the two in vitro assays and significant correlation with in silico data. All tested substances were identified as agonists for human estrogen receptor α by methods in silico and in vitro, four substances showed a potentially higher estrogenic activity comparing to bisphenol A, two substances were identified as very weak antagonists of human androgen receptor and one compound showed a potential of agonistic activity to human androgen receptor. CONCLUSIONS: The study contributes to recent findings and brings new in silico and in vitro data of bisphenol A analogues, revealing that these analogous substances should be further tested as they may show similar or higher activity in vivo comparing to bisphenol A, which has been recently legislatively regulated.
- 650 _2
- $a benzhydrylové sloučeniny $x metabolismus $7 D001559
- 650 _2
- $a biotest $7 D001681
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a endokrinní disruptory $x metabolismus $7 D052244
- 650 _2
- $a alfa receptor estrogenů $x agonisté $x antagonisté a inhibitory $x metabolismus $7 D047628
- 650 _2
- $a nesteroidní estrogeny $x metabolismus $7 D004968
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fenoly $x metabolismus $7 D010636
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kejlová, Kristina $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
- 700 1_
- $a Bendová, Hana $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
- 700 1_
- $a Rucki, Marian $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
- 700 1_
- $a Kohout, Pavel $u Thomayer's Hospital, Prague, Czech Republic.
- 700 1_
- $a Vavrouš, Adam $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
- 700 1_
- $a Jírová, Dagmar $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic.
- 773 0_
- $w MED00168352 $t Neuro-endocrinology letters $x 0172-780X $g Roč. 37, Suppl1 (2016), s. 123-131
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28263540 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20240321093807 $b ABA008
- 999 __
- $a ok $b bmc $g 1238906 $s 984138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 37 $c Suppl1 $d 123-131 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- LZP __
- $a Pubmed-20170720